{5-tert-butoxy-4-(4-fluoro-phenylethynyl)-2-[3-(3-imidazol-1-yl-phenyl)-3-oxo-propionylamino]-phenyl}-carbamic acid tert-butyl ester | 335352-05-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: {5-tert-butoxy-4-(4-fluoro-phenylethynyl)-2-[3-(3-imidazol-1-yl-phenyl)-3-oxo-propionylamino]-phenyl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[4-[2-(4-fluorophenyl)ethynyl]-2-[[3-(3-imidazol-1-ylphenyl)-3-oxopropanoyl]amino]-5-[(2-methylpropan-2-yl)oxy]phenyl]carbamate
• CAS: 335352-05-1
• 化学式: C₃₅H₃₅FN₄O₅
• 分子量: 610.685
• InChiKey: YCAHWSBAUFWNPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  45
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  {5-tert-butoxy-4-(4-fluoro-phenylethynyl)-2-[3-(3-imidazol-1-yl-phenyl)-3-oxo-propionylamino]-phenyl}-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 8-(4-Fluoro-phenylethynyl)-7-hydroxy-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one
  参考文献：
  名称：

  Glutamate receptor antagonists

  摘要：

  这项发明涉及具有公式1的基本结构的化合物。 公式I的化合物被证明具有作为代谢型谷氨酸受体拮抗剂的活性。

  公开号：

  US06407094B1
• 作为产物：
  描述：

  tert-butyl 3-[3’-(1''H-imidazol-1''-yl)phenyl]-3-oxopropanoate 、 [2-amino-5-tert.-butoxy-4-(4-fluoro-phenylethynyl)-phenyl]-carbamic acid tert.-butyl ester 生成 {5-tert-butoxy-4-(4-fluoro-phenylethynyl)-2-[3-(3-imidazol-1-yl-phenyl)-3-oxo-propionylamino]-phenyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Glutamate receptor antagonists

  摘要：

  这项发明涉及具有公式1的基本结构的化合物。 公式I的化合物被证明具有作为代谢型谷氨酸受体拮抗剂的活性。

  公开号：

  US06407094B1

文献信息

• BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1224174A2

  公开（公告）日：2002-07-24
• US6407094B1
  申请人：——

  公开号：US6407094B1

  公开（公告）日：2002-06-18
• [EN] BENZODIAZEPINE DERIVATIVES<br/>[FR] DERIVES DE BENZODIAZEPINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2001029011A2

  公开（公告）日：2001-04-26

  The present invention relates to compounds of general formula (I) wherein X is a single bond or an ethynediyl group, wherein, in case X is a single bond, R1 is halogen or phenyl which is optionally substituted with halogen, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, or cyano; In case X is an ethynediyl group, R1 is phenyl, optionally substituted with halogen, lower alkyl, halo-lower alkyl, lower cycloalkyl, lower alkoxy or halo-lower alkoxy; R3 is a 5 or 6 membered aryl or heteroaryl which are optionally substituted. The compounds according to the present invention can be used for treating or preventing acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits.
• Glutamate receptor antagonists
  申请人：Hoffmann-la Roche Inc.

  公开号：US06407094B1

  公开（公告）日：2002-06-18

  The present invention relates to compounds of with a base structure of formula 1 The compounds of formula I are shown to have activity as metabotropic glutamate receptor antagonists.

  这项发明涉及具有公式1的基本结构的化合物。 公式I的化合物被证明具有作为代谢型谷氨酸受体拮抗剂的活性。
• Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 2. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists
  作者：Thomas J. Woltering、Geo Adam、Jürgen Wichmann、Erwin Goetschi、James N.C. Kew、Frédéric Knoflach、Vincent Mutel、Silvia Gatti

  DOI：10.1016/j.bmcl.2007.12.005

  日期：2008.2

  A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Replacement of a cyano group by a five-membered heterocycle produced compounds inhibiting the binding of [H-3]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both mGluR2 and mGluR3. Further modification to improve the physicochemical properties led eventually to compounds with the ability to reverse LY354740-mediated inhibition of field excitatory postsynaptic potentials in the rat dentate gyrus. (C) 2007 Elsevier Ltd. All rights reserved.